- In April 2023, Mycovia Pharmaceuticals, a company focused on women's health, announced the launch of its novel oral antifungal treatment for recurrent vulvovaginal candidiasis, offering a new option for patients with chronic yeast infections. This development aims to provide a more convenient and effective solution for recurring infections
- In March 2023, TherapeuticsMD, Inc., a women's health company, reported positive Phase 3 clinical trial results for a new non-antibiotic treatment for bacterial vaginosis, signaling potential for an alternative approach to managing this common condition. This advancement aims to reduce reliance on antibiotics and address resistance concerns
- In March 2023, Dare Bioscience, a biopharmaceutical company, announced a strategic partnership with a global pharmaceutical firm to accelerate the development and commercialization of its investigational intravaginal ring for bacterial vaginosis, aiming to provide a long-acting, patient-friendly therapeutic option. This collaboration is expected to improve product reach and patient adherence
- In February 2023, Shionogi Inc., a Japanese pharmaceutical company, received FDA approval for a new antibiotic for trichomoniasis with a simplified dosing regimen, offering a more convenient treatment option for patients and healthcare providers. This approval is expected to improve patient compliance
- In January 2023, Sebela Pharmaceuticals, Inc., a specialty pharmaceutical company, launched a new line of non-hormonal vaginal moisturizers and lubricants specifically designed for atrophic vaginitis, catering to patients who cannot use or prefer not to use estrogen-based therapies. This expansion offers a wider range of solutions for atrophic vaginitis management
